Abstract
At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Current Drug Targets
Title: PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Volume: 8 Issue: 9
Author(s): Douglas E. Vaughan, Bart M. De Taeye and Mesut Eren
Affiliation:
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Abstract: At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Export Options
About this article
Cite this article as:
Vaughan E. Douglas, De Taeye M. Bart and Eren Mesut, PAI-1 Antagonists: Predictable Indications and Unconventional Applications, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662364
DOI https://dx.doi.org/10.2174/138945007781662364 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendrimer-Based Contrast Agents for Molecular Imaging
Current Topics in Medicinal Chemistry Clinical Presentation, Quality of Care, Risk Factors and Outcomes in Women with Acute ST-Elevation Myocardial Infarction (STEMI): An Observational Report from Six Middle Eastern Countries
Current Vascular Pharmacology Gender Specificity, Genetic Variation of Single Nucleotide Polymorphisms, and Blood Lipid Parameters
Current Women`s Health Reviews Importance and Potential of Dentists in Identifying Patients at High Risk of Diabetes
Current Diabetes Reviews Manufacture of the Functional Noodle and its Effects on Postprandial 2h-blood Glucose and Serum Lipid Levels of Subjects with IGT
Current Nutrition & Food Science Resveratrol and Analogues: A Review of Antioxidant Activity and Applications to Human Health
Recent Patents on Food, Nutrition & Agriculture Sympathetic Overactivity in Patients with Chronic Renal Failure - The Culprit of Increased Cardiovascular Mortality?
Current Hypertension Reviews Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Current Diabetes Reviews Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes
Current Drug Discovery Technologies Diabetes and the Impairment of Reproductive Function: Possible Role of Mitochondria and Reactive Oxygen Species
Current Diabetes Reviews Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Fad Diets: Dietary Dilemmas, Predicaments, and Recommendations for its Use
Current Nutrition & Food Science The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]
Current Pharmaceutical Design Hypothalamic and Neuroendocrine Changes in Huntingtons Disease
Current Drug Targets Advances in Current Diabetes Proteomics: From the Perspectives of Label- free Quantification and Biomarker Selection
Current Drug Targets Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Vitamin D and Sepsis: From Associations to Causal Connections
Inflammation & Allergy - Drug Targets (Discontinued)